Open AccessMetabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans
Author(s) -
Voon Ong,
Sara Wills,
Deborah Watson,
Taylor Sandison,
Shawn D. Flanagan
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01390-21
Subject(s) - excretion , pharmacokinetics , feces , urine , medicine , pharmacology , metabolism , chemistry , endocrinology , biology , physiology , microbiology and biotechnology
Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida,Aspergillus , andPneumocystis spp. in recipients of blood and marrow transplantation. Studies using [14 C]-radiolabeled rezafungin were conducted in rats, monkeys, and humans to characterize the mass balance, excretion, and pharmacokinetics of [14 C]-rezafungin and to evaluate relative amounts of rezafungin metabolites compared with parent drug.